2cureX announces commercial collaboration with Gibson Oncology, USA
Press Releases Regulatory
2cureX AB (“2cureX”) is pleased to announce that the company has established a commercial collaboration with the US based drug discovery company Gibson Oncology LLC (“Gibson Oncology”). 2cureX will use its IndiTreat® technology to stratify colorectal cancer (CRC) patients for sensitivity to the anti-cancer drug LMP400. After testing in nine CRC patient samples, 2cureX has shown that the IndiTreat® technology can stratify patients based on LMP400 sensitivity. Gibson Oncology plans to launch a phase II trial in metastatic colorectal cancer (mCRC) in Denmark in 2019. 2cureX and Gibson Oncology are currently negotiating the financial terms.
Gibson Oncology has acquired the rights to the anti-cancer drug, LMP400 from the National Cancer Institute (NCI) National Institute of Health (NIH) in the US. NCI has successfully completed five Phase I clinical trials with LMP400. Gibson Oncology plans to launch a Phase II clinical trial in mCRC in 2019 in Denmark. LMP400 has the same molecular target as the well-known anti-cancer drug Irinotecan being a “workhorse” in the treatment of mCRC. LMP400 is a novel drug that has been designed to circumvent some of the serious side-effects associated with Irinotecan treatment. Moreover, development of resistance after short-term treatment with Irinotecan is a serious problem that LMP400 is expected to overcome.
Mark C. Rogers, Executive Chairman of Gibson Oncology states “we have finalized the production of LMP400 and are ready to launch a Phase II clinical trial in 2019. We will enroll mCRC patients that have become resistant to Irinotecan” Mark C. Rogers continues “2cureX has presented convincing data showing efficacy of LMP400 in 3D micro-tumors from liver metastasis obtained from colorectal patients, and we believe that stratification of the enrolled patients based on the IndiTreat assay will allow us to reach the clinical end-points faster with less patients enrolled. We therefore see huge potential in the collaboration with 2cureX”.
“We look forward to assist Gibson Oncology in stratifying patients in the upcoming mCRC clinical trial” says Ole Thastrup, CEO of 2cureX and continues “This is the first time we use the IndiTreat® test to stratify patients for clinical trials. IndiTreat® is developed to assist oncologists in designing the optimal treatment for the individual cancer patient using approved drugs or drug combinations. In the collaboration with Gibson Oncology we will conduct the IndiTreat® test with a novel, not yet approved drug. This opens a new exiting avenue for 2cureX”.
Phone: +46 40 615 14 15
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
Maarten van der Linden, CBO
Phone: +45 22 90 24 69
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 4th, 2019.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).
About Gibson Oncology
Gibson Oncology is a private oncology drug development company dedicated to bringing its novel, cost-effective, and very well-tolerated Indeno anti-cancer treatments to market. Gibson intends to develop these novel anti-cancer drugs in advanced-stage cancer patients as single agent and in combination treatments with both immunotherapy and targeted therapies.